Biopharmaceutical News and Research

RSS

PhoreMost announces two key appointments to strengthen leadership team

PhoreMost Limited, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has made two appointments to strengthen its leadership team, as the Company positions itself for growth.

From PhoreMost 3 Feb 2020

FDA gives clearance to IND application for Calibr's 'switchable' CAR-T cell therapy

Calibr, the drug discovery and development division of Scripps Research, today announced that the U.S. Food and Drug Administration has given clearance to the Investigational New Drug (IND) application for Calibr's "switchable" CAR-T cell therapy, which is being evaluated for the treatment of certain cancers, including relapsed/refractory B-cell malignancies such as non-Hodgkin lymphoma and chronic lymphocytic leukemia.

3 Feb 2020

Researchers identify novel cellular entry factor for AAV vector types

Researchers led by a team at Massachusetts Eye and Ear have identified a novel cellular entry factor for adeno-associated virus vector (AAV) types--the most commonly used viral vectors for in vivo gene therapy. AAVs are vectors-or vehicles--that are created from a virus that is made harmless by molecular engineering, and have shown promise transporting genetic therapy treatments to affected tissues.

23 Jan 2020

Synthego adopts good manufacturing practices for highest-quality genome engineering for clinical applications

Synthego, the genome engineering company, today announced it has adopted Good Manufacturing Practice standards to provide academic and industry partners with high-quality reagents for use in clinical research and development.

From Synthego Corporation 23 Jan 2020

Horizon Discovery enters into licensing agreement with NGM for GS knockout CHO K1 cell line

Horizon Discovery Group plc, a global leader in the application of gene editing and gene modulation for cell line engineering, today announced that it will license its gene-edited Glutamine Synthetase knockout Chinese Hamster Ovary K1 cell line to NGM Biopharmaceuticals, Inc..

From Revvity 22 Jan 2020

Enterprise Therapeutics publishes open access paper on novel approach to treat cystic fibrosis

Enterprise Therapeutics Ltd, a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease, today announced the publication of its first peer-reviewed paper.

21 Jan 2020

SITESEEKER to be used for Otsuka’s therapeutics discovery programs

PhoreMost will deploy its in-house expertise and next-generation phenotypic screening platform, SITESEEKER, in disease-relevant pathways nominated by Otsuka.

From PhoreMost 21 Jan 2020

Mayo Clinic launches Clinical Data Analytics Platform to improve the health of patients

Mayo Clinic announced the Clinical Data Analytics Platform as the first venture under the Mayo Clinic Platform, a strategic initiative to improve health care through insights and knowledge derived from data.

14 Jan 2020

Airway Therapeutics receives funding to advance BPD treatment

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the injury cycle of inflammation for patients with respiratory and inflammatory diseases, announced today the closing of a $15.5 million oversubscribed Series C financing round.

8 Jan 2020

Pancreatic cancer cells release signal to suppress immune system's attack on tumors

A key immune signal has a previously unknown role in turning off the immune system's attack on pancreatic cancer cells, a new study finds.

8 Jan 2020

AI Therapeutics reports considerable progress on LAM-001 and LAM-004 clinical trials

AI Therapeutics is a clinical-stage biopharmaceutical company that has created an artificial intelligence-driven drug development platform for matching drugs to new indications.

7 Jan 2020

Boehringer Ingelheim to use PhoreMost's SITESEEKER platform in new collaboration

PhoreMost to deploy its SITESEEKER platform to identify novel targets for Boehringer Ingelheim’s discovery programs.

From PhoreMost 7 Jan 2020

Drug trial seeking treatment option for hyperphagia in patients with Prader-Willi Syndrome

One in every 15,000 children is affected by Prader-Willi syndrome (PWS), a complex, genetic endocrine condition caused by a disorder of chromosome 15. It's non-inheritable, meaning the condition isn't passed down from a family member.

3 Jan 2020

GB Sciences announces preclinical results of promising formulations for Parkinson's disease

GB Sciences, Inc. announced significant preclinical results for their Parkinson's disease ("PD") formulations from the midterm report for their preclinical study being performed by Dr. Lee Ellis of the National Research Council in Halifax, Nova Scotia, CANADA.

22 Dec 2019

IONTAS antibody for the treatment of B-Cell ALL receives approval for clinical trials

IONTAS Limited, a leader in the discovery and optimization of fully human antibodies, has been informed that International Biotechnology Center Generium, a leading Russian biopharmaceutical company, focused on developing and commercializing pharmaceutical products for the treatment of orphan diseases and cancer, has received approval from the Russian Health Authorities to initiate clinical trials with its CD3/CD19 bispecific antibody for the treatment of B-Cell Acute Lymphoblastic Leukemia.

From FairJourney Biologics 11 Dec 2019

New joint venture aims to develop implantable cell therapies for debilitating conditions with no cure

Mayo Clinic and W. L. Gore & Associates Inc., a global materials science company, have formed a joint venture to advance the development of implantable cell therapies to treat debilitating conditions with no cure. Avobis Bio will combine Mayo Clinic's clinical and cell expertise and Gore's expertise in material sciences to address some of the most challenging medical issues.

10 Dec 2019

Control and Monitor Nanoparticle, Biopharmaceutical and Polymer Product Process

In this interview, Jason Lin, Application Scientist from Wyatt Technology, talks to News-Medical about the new ultraDAWN that is a breakthrough in monitoring nanoparticle biopharmaceutical and polymer product process.

From Waters | Wyatt Technology 10 Dec 2019

US pharmaceutical industry continues to shine according to CPhI 2019 Annual Report

The US pharmaceutical industry continues to lead its global peers in terms of innovation and competitiveness, while still ranking high in overall growth potential despite its mature status, according to the results of a survey of 350 global pharmaceutical industry executives published as part of the recently released CPhI 2019 Annual Report.

From LabVantage Solutions 6 Dec 2019

Pharma’s take on the Pelosi drug-pricing bill: Fair warning or fearmongering?

House Speaker Nancy Pelosi's flagship proposal to curb prescription drug prices, the "Lower Drug Costs Now Act" - H.R. 3 - could come up for a vote in the chamber this month.

5 Dec 2019

Experimental therapies offer patients a greater chance of surviving Ebola virus disease

The investigational therapeutics mAb114 and REGN-EB3 offer patients a greater chance of surviving Ebola virus disease compared to the investigational treatment ZMapp, according to published results from a clinical trial conducted in the Democratic Republic of the Congo.

2 Dec 2019